Salix Pharmaceuticals Announces Issuance of Xifaxan(R) Patent.RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SLXP) today announced the issuance of a patent, entitled "Polymorphous polymorphous /poly·mor·phous/ (-mor´fus) polymorphic.
polymorphic. Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations", by the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property . This patent, assigned patent number US 7,045,620, is believed to extend the patent coverage of the current form of rifaximin, which we market in the United States under the tradename XIFAXAN(R), until May 22, 2024. Alfa Wassermann S.p.A., the patent owner, has licensed rights to rifaximin in the United States to Salix Pharmaceuticals. The patent is a composition of matter and process patent that covers several physical states of XIFAXAN.
"The issuance of this patent is an important component of our XIFAXAN Life Cycle Management program," stated Carolyn Logan, President and Chief Executive Officer. "We continue to move forward with increased confidence in our efforts to discover, develop and commercialize XIFAXAN to its fullest potential."
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina For other uses of this name, see Raleigh.
Raleigh (IPA: /ˈrɑli/, ral-ee) is the capital of the State of North Carolina and the county seat of Wake County. , develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's 150-member gastroenterology specialty sales and marketing team.
Salix markets COLAZAL(R) Capsules 750 mg, XIFAXAN(R) (rifaximin) tablets 200 mg, VISICOL(R) Tablets, OSMOPREP(TM) Tablets, AZASAN(R), Anusol-HC(R)Cream 2.5%, Anusol-HC(R) 25 mg Suppository suppository /sup·pos·i·to·ry/ (su-poz´i-tor?e) an easily fusible medicated mass to be introduced into a body orifice, as the rectum, urethra, or vagina.
n. , Proctocort(R) Cream 1% and Proctocort(R) Suppositories suppositories,
n.pl solid capsules made of materials that melt at body temperature and are used to deliver medicinal substances into the rectum. . MOVIPREP(R) and granulated gran·u·late
v. gran·u·lat·ed, gran·u·lat·ing, gran·u·lates
1. To form into grains or granules.
2. To make rough and grainy.
v.intr. mesalamine are under development.
For full prescribing information on Salix products, please visit www.salix.com.
Salix trades on the Nasdaq National Market under the ticker symbol Ticker Symbol
An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors "SLXP". For more information please contact the Company at 919-862-1000 or visit our web site at www.salix.com. Information on our web site is not incorporated in our SEC filings.
Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include management of rapid growth, risks of regulatory review and clinical trials, market acceptance for approved products, intellectual property risks, and the need to acquire additional products. The reader is referred to the documents that the Company files from time to time with the Securities and Exchange Commission.